Stock MACK MERRIMACK PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Merrimack Pharmaceuticals, Inc.

Equities

MACK

US5903282094

Real-time Estimate Cboe BZX
Other stock markets
 20:16:35 10/05/2024 BST 		5-day change 1st Jan Change
15.12 USD +0.30% Intraday chart for Merrimack Pharmaceuticals, Inc. +0.83% +12.79%
05-09 Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Payable on or About May 17, 2024 CI
03-27 Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution
BU
Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Payable on or About May 17, 2024
CI
Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution
BU
Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan
MT
Merrimack Receives $225 Million Milestone Payment from Ipsen
BU
Merrimack Reports Full Year 2023 Financial Results
BU
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Merrimack Reports Ipsen Announcement of Approval by The US FDA of Onivyde Plus 5 Fluorouracil/Leucovorin and Oxaliplatin as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma
AQ
Merrimack Pharmaceuticals to Receive $225 Million Milestone Payment From Ipsen
MT
Merrimack Pharmaceuticals to Get $225 Million Milestone Payment After FDA's Supplemental NDA Approval
DJ
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
BU
Merrimack Pharmaceuticals Insider Bought Shares Worth $627,125, According to a Recent SEC Filing
MT
Merrimack Reports Third Quarter 2023 Financial Results
BU
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to S&P Global BMI Index
CI
Insider Buy: Merrimack Pharmaceuticals
MT
Merrimack Reports Second Quarter 2023 Financial Results
BU
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 3000E Growth Index
CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell Small Cap Completeness Index
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MACK Stock
  4. News Merrimack Pharmaceuticals, Inc.